Skip to main content
    F

    Fulcrum Therapeutics Inc (FULC)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.70
    +0.02 (+0.54%)

    Market Cap: $281.09M

    Last updated: Nov 06, 2026 at 4:10 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    60%(18/30)
    Avg Surprise
    +39.48%

    Upcoming Estimates

    Period ending Dec 31, 2026
    EPS Consensus$-0.02
    Range$-0.18 - $0.12
    3 analysts
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Last 12 of 31 reported quarters and 1 upcoming estimate
    PeriodReportedEst.RangeSurpriseB/MAnalystsRevisionsYoY
    Dec 26EST
    		-$-0.02$-0.18 - $0.12--3--
    Sep 26
    Reported Nov 4
    		$-0.31$-0.10$-0.13 - $-0.08-210.00%Miss2
    1
    0
    30d
    		+0.0%
    Jun 26
    Reported Jul 30
    		$-0.29$-0.21$-0.31 - $-0.04-36.48%Miss7
    4
    0
    30d
    		-2.4%
    Mar 26
    Reported Apr 27
    		$-0.25$-0.30$-0.38 - $-0.24+16.67%Beat11
    3
    5
    30d
    		+10.7%
    Dec 25
    Reported Feb 24
    		$-0.31$-0.31$-0.33 - $-0.25-1.47%Miss11
    2
    1
    30d
    		+0.0%
    Sep 25
    Reported Oct 29
    		$-0.31$-0.29$-0.34 - $-0.26-6.90%Miss8
    5
    1
    30d
    		+32.6%
    Jun 25
    Reported Jul 29
    		$-0.28$-0.29$-0.31 - $-0.26+3.45%Beat8
    1
    0
    30d
    		-132.2%
    Mar 25
    Reported May 1
    		$-0.28$-0.29$-0.31 - $-0.26+3.45%Beat2
    0
    1
    30d
    		+34.9%
    Dec 24
    Reported Feb 25
    		$-0.31$-0.29$-0.34 - $-0.23-7.53%Miss6
    4
    2
    30d
    		+22.5%
    Sep 24
    Reported Nov 13
    		$-0.46$-0.40$-0.47 - $-0.37-15.00%Miss9
    No revisions (30d)
    		-17.9%
    Jun 24
    Reported Jul 31
    		$0.87$0.06$-0.46 - $0.74+1350.00%Beat8
    No revisions (30d)
    		+328.9%
    Mar 24
    Reported May 13
    		$-0.43$-0.44$-0.46 - $-0.39+2.27%Beat8
    No revisions (30d)
    		-4.9%
    Dec 23
    Reported Feb 27
    		$-0.40$-0.43$-0.50 - $-0.38+6.98%Beat7
    No revisions (30d)
    		+20.0%

    Key Metrics

    Valuation
    P/E Ratio-3.20EV/EBITDAN/A
    Price/FCF-4.27xFCF Yield-23.44%
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-32.40%ROICN/A
    Financial Health
    Debt/Equity0.00xInterest CoverageN/A
    Current Ratio31.35xQuick Ratio31.35x
    Trading Statistics
    Beta2.77Avg Volume1.42M
    52-Week High$15.7452-Week Low$2.83

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$3.71
    SMA 20$3.70
    SMA 50$3.75
    SMA 200$5.69
    EMA 10$3.71
    EMA 20$3.71
    EMA 50$3.77
    EMA 200$5.18

    MACD

    Line: -0.01Signal: -0.01Hist: 0.00

    ADX

    ADX: 8.2+DI: 16.5-DI: 19.7

    Aroon & PSAR

    Aroon Up76.0
    Aroon Down68.0
    PSAR$3.77

    Bollinger Bands

    Upper Band$3.78
    Lower Band$3.62
    %B Position422%(Upper)
    Band Width0.50

    RSI (14-Day)

    Neutral
    48.4

    Momentum Oscillators

    Stoch %K52.5
    Stoch %D55.9
    Williams %R-57.6
    ROC (10d)0.5%
    Momentum0.02
    CCI (20d)-11.5
    MFI (14d)46.6

    Volatility Measures

    ATR (14d)$0.07(2.0%)
    StdDev (20d)0.04
    Hist Vol20.2%(Moderate)

    Volume Flow

    VWAP$3.70
    OBV-6.1M
    AD Line-14.8M
    CMF (20d)-0.164

    Volume Metrics

    Avg Vol (20d)1.3M
    Vol Ratio0.7x
    VWMA (20d)$3.70

    Pivot Points

    R3$3.85
    R2$3.81
    R1$3.75
    Pivot Point$3.71
    S1$3.64
    S2$3.60
    S3$3.54

    Advanced Oscillators

    TSI-2.68
    Ultimate Osc44.8
    KST-8.28

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$80.00M$0$871,000$759,000
    Cost of Revenue$0$0$-300,000$0$0$0$369,000$0$0$0$508,000$0
    Gross Profit$0$0$300,000$0$0$0$-369,000$0$80.00M$0$871,000$759,000
    Operating Expenses$29.31M$22.19M$22.69M$21.86M$19.82M$20.40M$19.43M$25.13M$27.51M$29.83M$28.86M$28.20M
    R&D$12.44M$14.08M$15.42M$14.30M$12.99M$13.40M$11.71M$14.64M$17.26M$19.77M$19.00M$18.24M
    SG&A$7.46M$8.10M$7.28M$7.56M$6.83M$7.00M$7.72M$8.42M$10.25M$10.06M$9.86M$9.96M
    Operating Income$-29,310,000$-22,186,000$-22,693,000$-21,858,000$-19,815,000$-20,403,000$-19,429,000$-25,126,000$52.49M$-29,834,000$-27,992,000$-27,440,000
    Interest Income$3.13M$3.29M$2.36M$2.26M$2.52M$2.75M$2.86M$3.43M$2.92M$2.96M$3.24M$3.42M
    Interest Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Income Before Tax$-26,179,000$-18,891,000$-20,334,000$-19,595,000$-17,296,000$-17,655,000$-16,568,000$-21,696,000$55.41M$-26,870,000$-24,756,000$-24,017,000
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-26,179,000$-18,891,000$-20,334,000$-19,595,000$-17,296,000$-17,655,000$-16,568,000$-21,696,000$55.41M$-26,870,000$-24,756,000$-24,017,000
    EBITDA$-29,905,000$-22,615,000$-22,729,000$-22,098,000$-20,556,000$-20,949,000$-20,005,000$-25,909,000$51.73M$-30,516,000$-28,812,000$-28,494,000
    EBIT$-29,310,000$-22,186,000$-22,693,000$-21,858,000$-19,815,000$-20,403,000$-19,429,000$-25,126,000$52.49M$-29,834,000$-27,992,000$-27,440,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about FULC

    News

    Fulcrum Therapeutics, Inc. SEC Filing (Nov 5, 2026)

    Fulcrum Therapeutics, Inc. filed an S-4 Form, a Notice of Effectiveness, with the SEC, which became effective on November 4, 2026...

    Stock Titan•11/5/26•Neutral

    Fulcrum Therapeutics, Inc. (FULC) Seasonal Returns Chart - Yahoo Finance

    The article provides a seasonal returns chart for Fulcrum Therapeutics, Inc. (FULC), displaying the average monthly price return from 2019 to 2026. As of the market open at 10:15:36 a.m. EST...

    Yahoo! Finance Canada•10/31/26•Neutral

    Fulcrum Therapeutics, Inc. (FULC) Seasonal returns chart

    This article from Yahoo Finance presents a seasonal returns chart for Fulcrum Therapeutics, Inc. (FULC). It displays the average monthly price return for the company's stock from 2019 to 2026. The page also includes...

    Yahoo Finance UK•10/31/26•Neutral

    Amendment: SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc.

    Quantisnow reported an amendment to SEC Form SCHEDULE 13G/A filed by Fulcrum Therapeutics Inc. (FULC). The report includes historical stock performance after previous FULC headlines...

    Quantisnow•10/29/26•Neutral

    Bank of America amends its passive stake report on Fulcrum Therapeutics (FULC).

    Bank of America Corporation has filed an amended Schedule 13G/A, disclosing a 1.5% beneficial ownership in Fulcrum Therapeutics, Inc. (FULC). This amounts to 1,114,867 common shares...

    Stock Titan•10/28/26•Neutral

    FULC Valuation and Fair Value

    P/E
    -3.2x
    P/FCF
    -4.3x
    P/B
    0.9x
    See GNG's fair value

    FULC Profitability: Margins, ROIC and FCF

    Operating margin
    0.0%
    Net margin
    0.0%
    ROE
    -32.4%
    FCF yield
    -23.4%

    FULC Competitors

    CompanyTicker
    Prelude Therapeutics IncPRLD
    Arcturus Therapeutics Holdings IncARCT
    Kyverna Therapeutics, Inc. Common StockKYTX
    Ocugen IncOCGN
    SAB Biotherapeutics IncSABS
    Precision BioSciences IncDTIL
    Sanara Medtech IncSMTI
    Nautilus Biotechnology IncNAUT

    Sector: Healthcare

    FULC Analyst Ratings

    Consensus
    Hold
    Analysts
    6
    Strong Buy
    0
    Buy
    0
    Hold
    5
    Sell
    0
    Strong Sell
    1

    FULC Bull Case vs Bear Case

    Bear case

    • FULC beat EPS estimates in 37.5% of its last 8 reported quarters.
    • FULC's quarterly revenue changed -100.0% year over year.

    FULC Earnings: Beat Rate and Next Report

    Beat rate
    3 of 8 quarters (37.5%)
    Average surprise
    -29.9%
    EPS estimate (fiscal period ending Dec 31, 2026)
    $-0.02

    FULC Earnings Date

    FULC reports Feb 22, 2027, after the close. The date is estimated.

    FULC Earnings Call

    The latest FULC earnings call transcript on file is labeled 2026Q1.

    Read the 2026Q1 transcript

    FULC ETF Holders

    GNG tracks 10 ETFs that hold FULC. The largest weights:

    1. abrdn Healthcare Investors (HQH), 0.47% of the fund
    2. Fidelity Enhanced Small Cap Core ETF (FESM), 0.03% of the fund
    3. iShares Biotechnology ETF (IBB), 0.02% of the fund
    4. Vanguard Russell 2000 Index Fund ETF Shares (VTWO), 0.02% of the fund
    5. Vanguard Total Stock Market Index Fund Admiral Shares (VTSAX), <0.01% of the fund
    Open the ETF Stock Exposure tool for FULC

    See insider activity

    Frequently Asked Questions About FULC

    When does FULC report earnings?

    Fulcrum Therapeutics Inc (FULC) is expected to report earnings on Feb 22, 2027.

    Does FULC pay dividends?

    Fulcrum Therapeutics Inc (FULC) does not currently pay a regular dividend.

    What is FULC's market cap?

    Fulcrum Therapeutics Inc (FULC) has a market capitalization of $281.09M with a current stock price of $3.70.

    Related stocks

    Sector: Healthcare

    All stocks starting with F

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In